menu
    • menu

    Company profile for Arcellx

    NEW Drugs in Dev: 5
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Arcellx is a privately held development-stage company founded in 2015 & located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, & responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across ...
    Arcellx is a privately held development-stage company founded in 2015 & located in Montgomery County, Maryland. The Arcellx team is devoted to providing patients with superior immune cell therapies through scientific innovation, accelerated development, & responsible patient care. Although our initial clinical focus is cancer therapy, we are committed to extending our Antigen- Receptor Complex T cell (ARC-T) therapies across a broad spectrum of human disease. Our vision is to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, & reprogrammed throughout the course of disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ArcellxUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    25 West Watkins Mill Road, Suite A Gaithersburg, MD 20878
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.arcellx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    ChemTides

    Not Confirmed

    envelop Contact Supplier

    ChemTides

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gilead Sciences to Acquire Arcellx
    Gilead Sciences to Acquire Arcellx

    24 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260223744889/en/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel

    BUSINESSWIRE
    24 Feb 2026
    Share Share
    Arcellx Demonstrates Target Specificity of Anito-Cel's D-Domain
    Arcellx Demonstrates Target Specificity of Anito-Cel's D-Domain

    04 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-04/arcellx-announces-late-breaking-presentation-at-tandem-demonstrating-unique-high-target-specificity

    PHARMIWEB
    04 Feb 2026
    Share Share
    Arcellx To Discuss Early CAR T Access For Multiple Myeloma
    Arcellx To Discuss Early CAR T Access For Multiple Myeloma

    21 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260121747816/en/Arcellx-to-Advance-the-Conversation-on-Its-Platform-and-the-Importance-of-Early-CAR-T-Access-for-Patients-with-Multiple-Myeloma-During-the-2026-Tandem-Meetings

    BUSINESSWIRE
    21 Jan 2026
    Share Share
    Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma
    Arcellx Reveals Positive Results In iMMagine-1 Study in Myeloma

    06 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251206931756/en/Arcellx-Announces-New-Positive-Data-for-Its-iMMagine-1-Study-in-Patients-with-Relapsed-andor-Refractory-Multiple-Myeloma

    BUSINESSWIRE
    06 Dec 2025
    Share Share
    Arcellx Hosts IR Event at 67th ASH Annual Meeting
    Arcellx Hosts IR Event at 67th ASH Annual Meeting

    18 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251118380200/en/Arcellx-to-Host-Investor-Relations-Event-During-the-67th-ASH-Annual-Meeting-and-Exposition

    BUSINESSWIRE
    18 Nov 2025
    Share Share
    J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T
    J&J, Legend Pull ASH Paper Comparing Carvykti Against Rival CAR-T

    12 Nov 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/jj-legend-withdraw-ash-abstract-assessing-carvykti-against-gilead-arcellxs-rival-car-t

    FIERCE PHARMA
    12 Nov 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search